The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: ChiCGB vs BEAM in High-risk or R/R Lymphomas
Official Title: ChiCGB Versus BEAM With Autologous Stem-Cell Transplantation in High-risk Hodgkin and Non-Hodgkin Lymphoma - A Prospective, Multi-centered, Randomized Clinical Trial
Study ID: NCT05466318
Brief Summary: High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) plays a vital role in treating high-risked or relapsed/refractory lymphoma. Our previous study showed chidamide combined with cladribine, gemcitabine, and busulfan (ChiCGB) as conditioning therapy improved the survival of these patients. So we designed this trial to verify if ChiCGB were better than BCNU, etoposide, cytarabine, and melphalan (BEAM). Patients with diffuse large B cell or extra-nodal NK/T cell Lymphoma who consent to this study will be randomized into the trial group who receive ChiCGB or the control group whom receive BEAM. Patients will be followed for up to 2 years after the hematopoietic cell transplantation (HCT).
Detailed Description:
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
People's Hospital of Deyang City, Deyang, Deyang, China
Chengdu Third People's Hospital, Chendu, Sichuan, China
West China Hospital, Sichuan University, Chendu, Sichuan, China
Chengdu First People's Hospital, Chengdu, Sichuan, China
PLA Western Theater Command General Hospital, Chengdu, Sichuan, China
Dazhou Central Hospital, Dazhou, Sichuan, China
Southwest Medical University, Luzhou, Sichuan, China
Central Hospital of Mianyang City, Mianyang, Sichuan, China
Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
Zigong First People's Hospital, Zigong, Sichuan, China
Guangyuan Central Hospital, Guangyuan, Sihcuan, China